ATE462723T1 - Pharmazeutische zusammensetzung zur herabsetzung des blutzuckerspiegels - Google Patents
Pharmazeutische zusammensetzung zur herabsetzung des blutzuckerspiegelsInfo
- Publication number
- ATE462723T1 ATE462723T1 AT04772797T AT04772797T ATE462723T1 AT E462723 T1 ATE462723 T1 AT E462723T1 AT 04772797 T AT04772797 T AT 04772797T AT 04772797 T AT04772797 T AT 04772797T AT E462723 T1 ATE462723 T1 AT E462723T1
- Authority
- AT
- Austria
- Prior art keywords
- polypeptide
- pharmaceutical composition
- blood sugar
- ligand
- lowering blood
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
- C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
- G01N2333/726—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/04—Endocrine or metabolic disorders
- G01N2800/042—Disorders of carbohydrate metabolism, e.g. diabetes, glucose metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Obesity (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004056452 | 2004-03-01 | ||
JP2004240607 | 2004-08-20 | ||
PCT/JP2004/012848 WO2005083070A1 (ja) | 2004-03-01 | 2004-09-03 | 血糖値の低下に供される医薬組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE462723T1 true ATE462723T1 (de) | 2010-04-15 |
Family
ID=34914478
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT04772797T ATE462723T1 (de) | 2004-03-01 | 2004-09-03 | Pharmazeutische zusammensetzung zur herabsetzung des blutzuckerspiegels |
Country Status (6)
Country | Link |
---|---|
US (1) | US20080004227A1 (de) |
EP (1) | EP1731602B1 (de) |
JP (1) | JP4757190B2 (de) |
AT (1) | ATE462723T1 (de) |
DE (1) | DE602004026360D1 (de) |
WO (1) | WO2005083070A1 (de) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102438599B (zh) * | 2009-03-04 | 2015-01-21 | 迈雅营养品有限公司 | 通过降低血糖水平来控制糖尿病的营养组合物和方法 |
US8889739B2 (en) | 2010-07-09 | 2014-11-18 | President And Fellows Of Harvard College | Use of trans-palmitoleate in identifying and treating metabolic disease |
WO2012063820A1 (ja) | 2010-11-09 | 2012-05-18 | 持田製薬株式会社 | 血糖値上昇抑制剤 |
TW201325587A (zh) * | 2011-12-22 | 2013-07-01 | Kang Jian Biotech Corp Ltd | α-葡萄糖苷酶抑制劑 |
GB201310664D0 (en) | 2013-06-14 | 2013-07-31 | Mars Inc | Feline taste receptors |
WO2021241659A1 (ja) | 2020-05-29 | 2021-12-02 | 株式会社 Numt | Ffar4を高発現させた脂肪細胞及びその使用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6448005B1 (en) * | 1998-06-30 | 2002-09-10 | Millennium Pharmaceuticals, Inc. | 14723 Receptor, a novel G-protein coupled receptor |
EP1092024A2 (de) * | 1998-06-30 | 2001-04-18 | Millennium Pharmaceuticals, Inc. | Rezeptor 14273, ein g-protein-gekoppelter rezeptor |
JP4707839B2 (ja) * | 2000-02-07 | 2011-06-22 | 森永乳業株式会社 | 糖尿病予防治療剤 |
EP1305018A4 (de) * | 2000-08-02 | 2006-08-30 | Pharmanutrients | Methoden und zusammenstellungen zur prophylaxe und/oder behandlung von diabetes und zur glukoseregulierung |
WO2002067868A2 (en) * | 2001-02-26 | 2002-09-06 | Millennium Pharmaceuticals, Inc. | Methods for the treatment of metabolic disorders, including obesity and diabetes |
WO2002102364A1 (fr) * | 2001-06-18 | 2002-12-27 | Yamada, Sachiko | Preparations medicamenteuses agonistes ppar$g(g) |
US7214495B2 (en) * | 2002-02-14 | 2007-05-08 | Takeda Pharmaceutical Company Limited | Screening method |
JP4188720B2 (ja) * | 2002-02-14 | 2008-11-26 | 武田薬品工業株式会社 | 新規スクリーニング方法 |
WO2004004000A1 (ja) * | 2002-06-26 | 2004-01-08 | Fujitsu Limited | 半導体装置への電源接続構造 |
EP1584925B1 (de) * | 2003-01-17 | 2011-06-01 | Takeda Pharmaceutical Company Limited | Neues screening-verfahren |
JP4574177B2 (ja) * | 2003-01-17 | 2010-11-04 | 武田薬品工業株式会社 | 新規スクリーニング方法 |
-
2004
- 2004-09-03 WO PCT/JP2004/012848 patent/WO2005083070A1/ja active Application Filing
- 2004-09-03 JP JP2006510373A patent/JP4757190B2/ja not_active Expired - Fee Related
- 2004-09-03 AT AT04772797T patent/ATE462723T1/de not_active IP Right Cessation
- 2004-09-03 DE DE602004026360T patent/DE602004026360D1/de active Active
- 2004-09-03 US US10/591,186 patent/US20080004227A1/en not_active Abandoned
- 2004-09-03 EP EP04772797A patent/EP1731602B1/de not_active Not-in-force
Also Published As
Publication number | Publication date |
---|---|
DE602004026360D1 (de) | 2010-05-12 |
JPWO2005083070A1 (ja) | 2008-01-17 |
JP4757190B2 (ja) | 2011-08-24 |
EP1731602A4 (de) | 2007-05-02 |
EP1731602B1 (de) | 2010-03-31 |
US20080004227A1 (en) | 2008-01-03 |
EP1731602A1 (de) | 2006-12-13 |
WO2005083070A1 (ja) | 2005-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2005084109A3 (en) | Cancer specific gene mh15 | |
Zhao et al. | Effects of alpha-lipoic acid on spatial learning and memory, oxidative stress, and central cholinergic system in a rat model of vascular dementia | |
GB0213612D0 (en) | Organic compounds | |
WO2008030273A3 (en) | Compositions and methods for diagnosis and treatment of type 2 diabetes | |
BRPI0519241A2 (pt) | agonistas, composiÇÕes, mÉtodos e usos de glp-1 | |
TW200606427A (en) | Voltammetric systems for assaying biological analytes | |
WO2006063042A3 (en) | Selecting patients for therapy with a her inhibitor | |
EA200701469A1 (ru) | Комбинированная терапия для лечения диабета и родственных ему состояний и для лечения состояний, улучшаемых увеличением уровня glp-1 крови | |
WO2010054777A3 (en) | System and method for determining optimal insulin profiles | |
WO2005085860A3 (en) | New proliferation markers in clinical practice and their use for cancer prognosis or diagnosis | |
ATE502646T1 (de) | Fgfr agoniste | |
WO2009090553A3 (en) | Compositions and methods of detecting post-stop peptides | |
EA200802167A1 (ru) | Лекарства и применения | |
WO2005121362A3 (en) | Method for selectively quantifying vegf isoforms in a biological sample and uses thereof. | |
WO2004097429A3 (en) | Apociii and the treatmentand diagnosis of diabetes | |
WO2008055491A3 (de) | Diagnose und risikostratifizierung von diabetes mellitus mittels mr-proadm | |
WO2006017171A3 (en) | Methods of diagnosing & treating obesity, diabetes and insulin resistance | |
ATE462723T1 (de) | Pharmazeutische zusammensetzung zur herabsetzung des blutzuckerspiegels | |
WO2006116083A3 (en) | The 1, 5-anhydroglucitol (1, 5-ag) assay and a1c/1. 5-ag assay combination for measuring blood glucose excursions in general and postprandial hyperglycemia in diabetic patients | |
WO2008060400A3 (en) | Sirtuin polymorphisms and methods of use thereof | |
AU2003296424A1 (en) | Neurotoxic amino acid or neurotoxic derivative thereof associated with neurological disorders | |
Wang et al. | Warfarin resistance in Rattus losea in Guangdong province, China | |
WO2008027379A3 (en) | Indicators of sirtuin activity and methods of use thereof | |
DK1824501T3 (da) | Proteinhydrolysat med antidiabetisk virkning | |
WO2004069194A3 (en) | Use of the oxidoreductase ncb50r for diagnosings and treating diabetes |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |